Biomarkers in Thoracic Oncology" is an interactive, gamified activity designed to enhance knowledge of current and emerging biomarkers in thoracic oncology. Through a quiz format featuring multiple-choice questions, participants receive immediate feedback and track progress on a leaderboard, fostering engaging learning on biomarker applications in clinical decision-making for thoracic cancers.

Course Accreditations

0.25 AMA PRA Category 1 Credit™ The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 0.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission. 0.25 Nursing Contact Hours Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 0.25 Contact Hours. 0.25 ABIM MOC II Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Course Summary

Faculty

Lei Deng   (MD, University of Washington, Fred Hutchinson Cancer Center)

Dr. Lei Deng is an assistant professor within the Thoracic, Head & Neck medical oncology group, at University of Washington and Fred Hutch Cancer Center. He is interested in clinical and translational thoracic cancer research focusing on novel biomarkers and therapeutics, particularly KRAS-mutated lung cancer. He is also interested in optimizing systemic therapy for patients undergoing curative surgery and definitive radiotherapy. Dr. Deng co-leads the early-career working group at IASLC's Career Development Committee since 2025.

Mohana Roy   (MD, Stanford Medicine)

Dr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in hematology and oncology. Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience -- from the moment a patient checks in, to how information about their care is conveyed, and how the complex process of getting cancer care can be made a bit more seamless. Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs) and their use to help clinical quality efforts, She is the recipient of both a clinical innovation award through Stanford and an American Society of Clinical Oncology (ASCO) Merit award. She is the Associate Medical Director for Quality at Stanford Cancer Center.

Siddhartha Devarakonda   (MD, Swedish Cancer Institute)

Dr. Sid Devarakonda trained and worked on faculty at the Washington University in St. Louis before joining Swedish Cancer Institute in Seattle as the Director of Thoracic Medical Oncology and Washington State University as an Associate Professor. His research is focused on understanding cancers utilizing sequencing technologies. He has been a part of consortia such as TCGA. He is particularly interested in understanding the molecular underpinnings of never-smoker lung cancer and mechanisms of treatment resistance in lung cancers.

Target Audience

Medical Oncologists
Surgeons
Radiation Oncologists
Pathologists
Oncology Fellows
Oncology Nurses
Nurse Practitioners
Physician Assistants
Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

Identify key current and emerging biomarkers used in the diagnosis and treatment of thoracic cancers.
Evaluate the clinical significance of specific biomarkers in guiding therapeutic decisions for patients with thoracic malignancies.
Apply biomarker knowledge to enhance personalized treatment strategies and improve patient outcomes in thoracic oncology.